Safety Data From the Phase 2B SunRISe-2 Study of TAR-200 in BCG-Unresponsive High-Risk NMIBC

Opinion
Video

The TAR-200 treatment has demonstrated a favorable safety profile in clinical trial, with primarily low-grade irritated voiding symptoms that are manageable and expected with intravesical therapy, without concerning systemic side effects, making it a promising new option to delay or reduce radical cystectomy in patients with BCG-unresponsive NMIBC.

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content